Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P, Hasan AN, Selvakumar A, O'Reilly RJ, Liu C, Cheung NV.

JCI Insight. 2018 Feb 22;3(4). pii: 97805. doi: 10.1172/jci.insight.97805. eCollection 2018 Feb 22.

2.

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).

Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D.

Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12.

3.

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

Hoseini SS, Dobrenkov K, Pankov D, Xu XL, Cheung NK.

Oncoimmunology. 2017 Apr 28;6(6):e1320625. doi: 10.1080/2162402X.2017.1320625. eCollection 2017.

4.

Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.

Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA.

Oncoimmunology. 2016 Aug 3;5(9):e1211221. eCollection 2016.

5.

Opportunities and challenges for TCR mimic antibodies in cancer therapy.

Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA.

Expert Opin Biol Ther. 2016 Aug;16(8):979-87. doi: 10.1080/14712598.2016.1176138. Epub 2016 Apr 27. Review.

6.

T cell receptor mimic antibodies for cancer therapy.

Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA.

Oncoimmunology. 2015 Jun 1;5(1):e1049803. eCollection 2016. Review.

7.

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA.

Nat Biotechnol. 2015 Oct;33(10):1079-86. doi: 10.1038/nbt.3349. Epub 2015 Sep 21.

8.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL.

Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006.

9.

The effect of diketopyrrolopyrrole (DPP) group inclusion in p-cyanophenyl end-capped oligothiophene used as a dopant in P3HT:PCBM BHJ solar cells.

Manninen VM, Heiskanen JP, Pankov D, Kastinen T, Hukka TI, Hormi OE, Lemmetyinen HJ.

Photochem Photobiol Sci. 2014 Oct;13(10):1456-68. doi: 10.1039/c4pp00207e.

PMID:
25078852
10.

Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA.

Clin Cancer Res. 2014 Aug 1;20(15):4036-46. doi: 10.1158/1078-0432.CCR-13-2756. Epub 2014 May 21.

11.

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.

Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA.

Blood. 2014 May 22;123(21):3296-304. doi: 10.1182/blood-2014-01-549022. Epub 2014 Apr 10.

12.

A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Shono Y, Tuckett AZ, Ouk S, Liou HC, Altan-Bonnet G, Tsai JJ, Oyler JE, Smith OM, West ML, Singer NV, Doubrovina E, Pankov D, Undhad CV, Murphy GF, Lezcano C, Liu C, O'Reilly RJ, van den Brink MR, Zakrzewski JL.

Cancer Discov. 2014 May;4(5):578-91. doi: 10.1158/2159-8290.CD-13-0585. Epub 2014 Feb 18.

13.

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA.

Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.

14.

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ.

Blood. 2012 Aug 23;120(8):1633-46. doi: 10.1182/blood-2011-11-394619. Epub 2012 May 23.

15.

[The clinical essence of the term "the initial manifestations of cerebral circulatory insufficiency"].

Pankov DD.

Zh Nevrol Psikhiatr Im S S Korsakova. 1996;96(6):12-5. Russian.

PMID:
9072886
16.
17.

[Study on structural gene expression in human insulinoma].

Chekhranova MK, Shuvalova ER, Ilína EN, Pankov DIu, Diabirova SB, Pankov IuA.

Vestn Ross Akad Med Nauk. 1994;(12):17-9. Russian.

PMID:
7742651
18.

[The role of paramedical personnel in detecting the early clinical forms of cerebral circulatory insufficiency].

Pankov DD.

Med Sestra. 1989 Sep;48(9):16-20. Russian. No abstract available.

PMID:
2593783
19.

[Syndromology and differential treatment of secondary cochleovestibulitis in patients with early clinical forms of cerebral circulatory insufficiency].

Pankov DD, Petrova EI, Kosiakov SIa, Poliakova TS, Skvortsova VI.

Vestn Otorinolaringol. 1989 Jan-Feb;(1):7-11. Russian.

PMID:
2785313
20.

[The genesis of early clinical forms of cerebral circulatory failure and the effectiveness of different courses of therapeutic measures].

Pankov DD, Petrova EI, Skvortsova VI, Kosiakov SIa.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1988;88(1):34-9. Russian.

PMID:
3364093
21.

[Secondary cochleovestibular neuritis as a sign of pathology of the major cerebral vessels].

Pankov DD, Petrova EI, Poliakova TS, Kuntsevich GI, Gogodze AB.

Vestn Otorinolaringol. 1987 Sep-Oct;(5):29-30. Russian. No abstract available.

PMID:
3424511
22.

[Organizational problems of the dispensary care of neurology patients].

Gusev EI, Vilenskiĭ BS, Dubrovskaia MK, Pankov DD, Nifontova LA.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(12):1872-4. Russian. No abstract available.

PMID:
3447406
23.

[Syndromology and potential differentiated therapy in the early clinical forms of cerebral circulatory insufficiency].

Pankov DD.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(9):1301-5. Russian.

PMID:
3425069
24.

[Cochleovestibular disorders in patients with early signs of cerebral circulatory insufficiency].

Petrova EI, Pankov DD, Kosiakov SIa.

Vestn Otorinolaringol. 1986 May-Jun;(3):21-4. Russian. No abstract available.

PMID:
3487865
25.

[Electroneuromyographic characteristics of the initial manifestations of cerebral circulatory insufficiency].

Skvortsova VI, Gusev EI, Pankov DD.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1986;86(9):1299-305. Russian.

PMID:
3776408

Supplemental Content

Loading ...
Support Center